×

Anthera Pharmaceuticals Announces Positive DSMB Review in Phase 3 SOLUTION Study of Sollpura™

HAYWARD, Calif., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that the Data and Safety Monitoring Board (DSMB) completed its first pre-planned safety review of the Phase 3 SOLUTION clinical study of Sollpura™ in cystic fibrosis patients with exocrine pancreatic insufficiency. The DSMB had “no concerns regarding safety of the data to date, and voted that the study continue without modification to the protocol or charter.”

This follows six positive reviews by a separate independent blisibimod DSMB for the CHABLIS-SC1 clinical study in patients with lupus and the BRIGHT-SC clinical study in patients with IgA nephropathy that recommended that the studies continue without modification, with the latest positive review occurring in June of this year.

About Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis. Additional information on the Company can be found at www.anthera.com.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2016. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Nikhil Agarwal of Anthera Pharmaceuticals, Inc. nagarwal@anthera.com or 510.856.5600 x5621

Source:Anthera Pharmaceuticals, Inc.